Quick Answer
FATE THERAPEUTICS INC reported Diluted EPS of $1.15 per share (loss) for fiscal year 2025.
FATE THERAPEUTICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.15 | +29.9% |
| 2024 | -$1.64 | +0.0% |
| 2023 | -$1.64 | +43.6% |
| 2022 | -$2.91 | -29.9% |
| 2021 | -$2.24 | -6.7% |
| 2020 | -$2.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.27 | +32.5% | +6.9% |
| June 30, 2025 | -$0.29 | +12.1% | +9.4% |
| March 31, 2025 | -$0.32 | +31.9% | +20.0% |
| September 30, 2024 | -$0.40 | +13.0% | -21.2% |
| June 30, 2024 | -$0.33 | +38.9% | +29.8% |
| March 31, 2024 | -$0.47 | -147.4% | -2.2% |
| September 30, 2023 | -$0.46 | +46.5% | +14.8% |
| June 30, 2023 | -$0.54 | +31.6% | -184.2% |
- FATE THERAPEUTICS INC showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, FATE THERAPEUTICS INC’s diluted eps has grown by 45.2% (from $2.10 per share (loss) to $1.15 per share (loss)).
- The most recent figure is from FATE THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: